HZNP News and Press, Horizon Therapeutics Public Limited Company From 11/01/22

--Company Recognized for Transparency and Best Practices Related to an Inclusive Culture-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has been named to Seramount’s (formerly Working Mother media) 2022 Inclusion Index. The Inclusion Index recognizes com...

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis PR Newswire WALTHAM, Mass. and DUBLIN , Oct. 27, 2022 /PRNewswire/ -- Q32 Bio , a clinical stage biotechnology company developi...

Summary The second patient death prompted Alpine to terminate any future development of davoceticept. It's prudent that Alpine stopped unfruitful developments early on to focus on lower-hanging fruits. Next year, Alpine is poised to run basket studies on ALPN303 which can move...

-- Separate analysis also being presented at ECTRIMS 2022 reinforces the efficacy of UPLIZNA in patients with genetic variations -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data from two analyses of the UPLIZNA Phase 3 pivotal trial being presented at the ...

-- Analysis presented at American Thyroid Association Annual Meeting (ATA 2022) shows during a two-year period, 4.9% of patients who completed a full course of TEPEZZA were later prescribed a second course -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced new da...

Summary HQH is able to generate strong and steady yield which is good enough to ignore the price loss suffered by this fund in a market that’s bearish overall. HQH is in a better position to hold up to its current price, and as it trades at a good discount to its NAV, chanc...

-- Real-world analysis of TEPEZZA use since U.S. Food and Drug Administration (FDA) approval evaluates percentage of people who received a second course of treatment -- -- Poster presentation on inflammatory TED to discuss impact on patients throughout the course of disease --...

-- Presentations will feature analyses from the pivotal Phase 3 study of UPLIZNA, including the relationship between B-cell subsets and NMOSD attacks -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new UPLIZNA analyses will be presented at the 38 th Congr...

Horizon Therapeutics ( NASDAQ: HZNP ) on Friday said it had lowered its FY 2022 adj. EBITDA guidance on account of changes in its classification of what it called acquired in-process research and development (IPR&D) and milestones expense. The company now expects adj. EB...

-- Dave Thomas Foundation for Adoption Also Names Horizon a Top 100 Adoption-Friendly Workplace -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to Newsweek’s 2022 Top 100 Most Loved Workplaces ® list for prioritizing respect,...